SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of slides that have been revised from an ICN presentation
first made to investors on or about May 16, 2001:
Hepatitis C Treatment Market Opportunity
-----------------------------------------------------------------------------
Royalties from Ribavirin
1997-2001 CAGR +135% E
[BAR GRAPH OMITTED - 1997 - $6M
1998 - $37M (Rebetron(R) Approved
in June 1998)
1999 - $109M
2000 - $155M
2001 - $180-190M E (1Q/01=$28M)]
-----------------------------------------------------------------------------
Financial Overview
-----------------------------------------------------------------------------
ICN Achieves Record Revenues in 2000
1995-2000 CAGR +24%
[BAR GRAPH OMITTED - 1995* - $273M
1996* - $347M
1997* - $527M
1998* - $696M
1999 - $747M
2000 - $800M]
* Excludes revenue from ICN Yugoslavia
-----------------------------------------------------------------------------
Financial Overview
-----------------------------------------------------------------------------
2000 Operating Income*
1995-2000 CAGR +31%
[BAR GRAPH OMITTED - 1995** - $47M
1996** - $43M
1997** - $64M
1998**(*) - $121M
1999 - $199M
2000 - $184M]
* Continuing Operations
(*) Excludes EE charges
** Excludes the results of operations of ICN Yugoslavia
-----------------------------------------------------------------------------
Financial Overview
-----------------------------------------------------------------------------
Statement of Income
Quarter Ended March 31
($ in millions except EPS) 2001 2000
Revenues $199.0 $192.3
Gross Profit 129.2 131.5
SG&A, Amortization & R&D 88.0 79.0
------------ ------------
Operating Income 41.2 52.5
Interest, net 10.8 12.5
Translation 0.4 1.6
------------ ------------
Pretax income before minority
interest 30.0 38.4
Income Taxes 9.3 11.1
Minority Interest (0.3) (0.1)
------------ ------------
Net Income before extraordinary
item $21 $27.4
============ ============
Diluted EPS $0.26 $0.34
-----------------------------------------------------------------------------
Financial Overview
-----------------------------------------------------------------------------
Consolidated Balance Sheet - Assets
($000's)
March December
2001 2000
----------- ------------
Cash $169,214 $155,585
Accounts receivable 194,322 225,639
Inventories 159,650 170,263
Prepaid expenses 15,793 13,929
----------- ------------
Current assets 583,979 565,416
Property, plant & equipment 379,119 367,229
Other assets 549,002 544,427
----------- ------------
Total assets $1,467,100 $1,477,072
============ ============
-----------------------------------------------------------------------------
Financial Overview
-----------------------------------------------------------------------------
Consolidated Balance Sheet
Liabilities and Stockholders' Equity
($000's)
March December
2001 2000
------------ ------------
Current liabilities $ 153,674 $ 158,777
Long-term debt 510,643 510,781
Other liabilities 44,733 50,320
------------ ------------
Total liabilities 709,050 719,878
Stockholders' equity 758,050 757,194
------------ ------------
Total liabilities and
stockholders' equity $1,467,100 $1,477,072
============ ============
-----------------------------------------------------------------------------